ABN Amro Investment Solutions Boosts Stake in IQVIA Holdings Inc. $IQV

ABN Amro Investment Solutions boosted its position in IQVIA Holdings Inc. (NYSE:IQV) by 51.1% in the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 9,557 shares of the medical research company’s stock after purchasing an additional 3,234 shares during the period. ABN Amro Investment Solutions’ holdings in IQVIA were worth $1,630,000 as of its most recent SEC filing.

Several other hedge funds have also recently added to or reduced their stakes in IQV. Ameliora Wealth Management Ltd. acquired a new position in shares of IQVIA during the 4th quarter valued at about $25,000. International Assets Investment Management LLC acquired a new position in IQVIA in the fourth quarter valued at $27,000. Gilpin Wealth Management LLC acquired a new position in shares of IQVIA in the 4th quarter valued at about $27,000. CrossGen Wealth LLC acquired a new stake in IQVIA during the 4th quarter worth approximately $28,000. Finally, Activest Wealth Management increased its position in shares of IQVIA by 590.0% in the fourth quarter. Activest Wealth Management now owns 138 shares of the medical research company’s stock worth $31,000 after acquiring an additional 118 shares in the last quarter. 89.62% of the stock is currently owned by hedge funds and other institutional investors.

IQVIA Trading Up 0.4%

Shares of IQVIA stock opened at $208.22 on Friday. The business has a fifty day simple moving average of $188.23 and a 200-day simple moving average of $187.38. The firm has a market cap of $34.75 billion, a price-to-earnings ratio of 25.80, a price-to-earnings-growth ratio of 1.86 and a beta of 1.20. IQVIA Holdings Inc. has a fifty-two week low of $154.50 and a fifty-two week high of $247.04. The company has a quick ratio of 0.75, a current ratio of 0.75 and a debt-to-equity ratio of 2.20.

IQVIA (NYSE:IQV) last announced its earnings results on Tuesday, May 5th. The medical research company reported $2.90 EPS for the quarter, beating the consensus estimate of $2.83 by $0.07. IQVIA had a return on equity of 30.50% and a net margin of 8.33%.The business had revenue of $4.15 billion during the quarter, compared to the consensus estimate of $4.10 billion. During the same period in the prior year, the business posted $2.70 earnings per share. IQVIA’s revenue was up 8.4% compared to the same quarter last year. IQVIA has set its FY 2026 guidance at 12.650-12.950 EPS. On average, equities analysts forecast that IQVIA Holdings Inc. will post 11.57 EPS for the current fiscal year.

IQVIA declared that its board has approved a stock buyback plan on Thursday, May 7th that authorizes the company to buyback $2.00 billion in shares. This buyback authorization authorizes the medical research company to purchase up to 6.8% of its stock through open market purchases. Stock buyback plans are generally an indication that the company’s board of directors believes its shares are undervalued.

Analysts Set New Price Targets

A number of research analysts have commented on the company. Mizuho boosted their price objective on IQVIA from $215.00 to $230.00 and gave the stock an “outperform” rating in a research note on Monday, July 13th. Evercore reaffirmed an “outperform” rating and issued a $185.00 price objective on shares of IQVIA in a research report on Wednesday, April 8th. Weiss Ratings upgraded shares of IQVIA from a “hold (c-)” rating to a “hold (c)” rating in a research note on Wednesday, July 15th. Morgan Stanley reaffirmed an “equal weight” rating and set a $200.00 target price (down from $225.00) on shares of IQVIA in a research report on Wednesday, June 17th. Finally, Deutsche Bank Aktiengesellschaft set a $240.00 target price on IQVIA in a research report on Thursday, July 9th. Thirteen investment analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $225.71.

About IQVIA

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.